An FDA-cleared implant for foot and ankle surgery is now being sold by SINTX
SINTX Technologies reported a 10x increase in third-quarter revenue year-over-year, with reduced operating losses. The company launched its FDA-cleared SiNAPTIC Foot & Ankle Osteotomy Wedge System and is exploring additional healthcare applications for its silicon nitride technology. SINTX also regained compliance with Nasdaq's equity requirement and raised approximately $5.5M in gross proceeds.
How this was made
The 30-second read
Why it matters
The Q3 results provide the first public quantitative evidence of commercial traction for the FDA‑cleared foot and ankle implant, signaling potential revenue expansion.
Market read
First‑report earnings with a dramatic revenue jump for a micro‑cap med‑tech firm; likely to generate short‑term buying interest.
What to watch
The company still reports a net loss and depends on future regulatory approvals for spinal and wound‑care applications.
Background
SINTX Technologies is a developer of silicon nitride ceramic biomaterials used in medical implants and industrial applications.
Ticker impact
SINTX Technologies reported third‑quarter revenue increasing more than tenfold year‑over‑year and a reduction in operating losses.
likely upward pressure as investors price in the revenue surge and improved margins
First‑report earnings with material revenue acceleration for a micro‑cap; market typically reacts positively to such beats.
Market effects
Highlights growing demand for silicon nitride orthopedic implants, potentially benefiting other med‑tech firms in the niche.
May boost investor interest in Utah‑based biotech and advanced materials companies.
Limited to the niche med‑tech segment; unlikely to affect broader indices.
Counterpoint
Revenue surge may be one‑off from limited‑use release; sustainability of growth remains uncertain.
Key entities
- ExecutiveEric Olson
CEO of SINTX who commented on the quarter's performance.


